Search

Your search keyword '"Leleu, A"' showing total 8,947 results

Search Constraints

Start Over You searched for: Author "Leleu, A" Remove constraint Author: "Leleu, A"
8,947 results on '"Leleu, A"'

Search Results

53. Alleviating the transit timing variation bias in transit surveys. I. RIVERS: Method and detection of a pair of resonant super-Earths around Kepler-1705

55. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

56. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

57. Listeria monocytogenes-associated spontaneous bacterial peritonitis in France: a nationwide observational study of 208 cases

58. Monitoring red wine maturation in oak barrels using 1H NMR-based metabolomics

59. Generation of IPi001-A/B/C human induced pluripotent stem cell lines from healthy amniotic fluid cells

61. Coherent Ising Machines with Optical Error Correction Circuits

67. Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts

70. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

71. The New Generation Planetary Population Synthesis (NGPPS). VI. Introducing KOBE: Kepler Observes Bern Exoplanets. Theoretical perspectives on the architecture of planetary systems: Peas in a pod

72. Six transiting planets and a chain of Laplace resonances in TOI-178

79. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

80. Inflammation and oxidative stress markers in type 2 diabetes patients with Advanced Carotid atherosclerosis

81. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

82. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

83. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

84. Planetary system LHS 1140 revisited with ESPRESSO and TESS

85. Collective and synchronous dynamics of photonic spiking neurons

86. Scaling advantage of nonrelaxational dynamics for high-performance combinatorial optimization

87. Model-Size Reduction for Reservoir Computing by Concatenating Internal States Through Time

88. Coherent Ising machines -- Quantum optics and neural network perspectives

89. Coherent Ising machines with error correction feedback

90. On the impact of tides on the transit-timing fits to the TRAPPIST-1 system

91. Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions

92. Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

95. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

96. Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions

97. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

98. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.

99. Prognostic models for short-term annual risk of severe complications and mortality in patients living with type 2 diabetes using a national medical claim database

100. Experimental observation of chimera states in spiking neural networks based on degenerate optical parametric oscillators

Catalog

Books, media, physical & digital resources